RxDoctor Payments Data

Tracy Smith

Adult Health · Saint Louis, MONPI 1255895496

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 300 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 29.6% of the total. Reporting peaked in 2024 at $2,645 and has fallen 97.2% since, to $73 in 2025.

$4,906in general payments, 2019–2025

Across 300 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$395
  • Johnson & Johnson$374
  • Gilead$349
  • Pfizer$337
  • Bristol Myers Squibb$322
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$4,77397%
  • Education$1333%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,906 in reported general payments places this provider in the 85th percentile of 555 adult health providers in Missouri.

See all adult health providers in Missouri

Medicare billing

Part B allowed, 2024
$26,120
Medicare patients
177
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin30$95,332
CreonLipase/Protease/Amylase14$58,394
LinzessLinaclotide76$51,095
ViberziEluxadoline18$34,263
Mesalamine69$20,266
TrulancePlecanatide14$16,325
MovantikNaloxegol Oxalate12$5,726
Dexlansoprazole DrDexlansoprazole16$4,697
Colestipol Hcl57$3,925
Balsalazide Disodium18$3,805
Cholestyramine LightCholestyramine17$1,719
Pantoprazole Sodium148$1,711
Omeprazole135$1,647
CholestyramineCholestyramine (With Sugar)18$1,200
Famotidine118$1,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Viberzi$1,450$143,753108 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$395$111,65844 claims
Redhill Biopharma Inc.Movantik$30$5,72612 claims
SandozLansoprazole$13$32913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 555 adult health providers in Missouri.

Other adult health in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →